President Trump's bout of COVID-19 launched countless headlines regarding the some of the leading experimental treatments he'd be receiving - therapeutics…
McAlinden Research PartnersOctober 13, 2020
Emerging market healthcare stocks were on fire earlier in the year. While they have taken a breather recently, MRP believes…
McAlinden Research PartnersSeptember 17, 2020
New developments in advanced methods of CRISPR, particularly in base and prime editing, continue to propel the popularity of the…
McAlinden Research PartnersSeptember 1, 2020
COVID-19 has been a gamechanger for telemedicine. A perfect storm scenario saw 5-10 years of progress take place over just…
McAlinden Research PartnersJuly 30, 2020
The rate at which new coronavirus infections are surging across Latin America, South Asia, and Africa suggests that emerging markets…
McAlinden Research PartnersJuly 20, 2020
Treatments utilizing Clustered Regularly Interspace Short Palindromic Repeats (CRISPR), continue to rack up clinical success. The latest research on blood…
McAlinden Research PartnersJune 16, 2020
Though many sectors have been whacked by the Coronavirus-related hurdles in 2020, research and development of the gene editing technology…
McAlinden Research PartnersMay 13, 2020
China is ramping up its manufacturing of medical goods, including masks, PPE, and ventilators, as it seeks to ship them…
McAlinden Research PartnersApril 28, 2020
All sizes of pharmaceutical firms from giants like Johnson & Johnson to young guns like Moderna, yet to bring their…
McAlinden Research PartnersApril 1, 2020
